42471-28-3

Usage

Uses

Used in Oncology:
Nimustine is used as an antineoplastic agent for the treatment of malignant brain tumors. It works by inhibiting the synthesis of DNA and RNA, thereby preventing the growth and proliferation of cancer cells.
Used in Pharmaceutical Industry:
Nimustine is used in the pharmaceutical industry as a key ingredient in the development of drugs for the treatment of brain tumors and other types of cancer. Its unique chemical structure and mechanism of action make it a valuable component in the fight against cancer.

Originator

Nidran,Sankyo,Japan,1979

Manufacturing Process

0.4 g of sodium nitrite was added with stirring, at 0°C to 5°C, to a solution of 450 mg of 1-(2-chloroethyl)-3-[(2-methyl-4-aminopyridin-5-yl)methyl]urea in 8 ml of 5% hydrochloric acid, and the reaction mixture was then stirred at 0°C to 10°C for an additional 1.5 hours.After completion of the reaction, the reaction mixture was made alkaline by the addition of sodium carbonate, whereupon crystals separated out in situ. The crystals were recovered by filtration, washed with water and then recrystallized from 6 ml of ethanol, to give 0.1 g of the pale yellow pure desired product having a decomposition point of 125°C.

Therapeutic Function

Antitumor, Antileukemic

InChI:InChI=1/C9H13ClN6O2.ClH/c1-6-12-4-7(8(11)14-6)5-13-9(17)16(15-18)3-2-10;/h4H,2-3,5H2,1H3,(H,13,17)(H2,11,12,14);1H

Upstream product

• 42471-43-2 1-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-3-(2-chloro-ethyl)-urea 

Relevant academic research and scientific papers

Concatamers for Immunemodulation

The invention relates to a polymeric, non-coding nucleic acid molecule for modulation of the activity of the human and animal immune system as well as a method for the manufacture thereof and a vaccine, comprising the polymeric, non-coding nucleic acid molecule, wherein polymeric, non-coding nucleic acid molecules may be understood as non-coding nucleic acid molecules, comprising at least four covalently bound molecules (tetramer) or are assemblies of more non-coding nucleic acid molecules (high molecular polymers) which are covalently bound to each other.

Nitrosourea derivative

Nitrosourea derivatives represented by the formula STR1 wherein A represents a group of the formula B--Y-- in which B is an unsaturated 5- or 6-membered heterocyclic group which has the as hetero atom at least one nitrogen atom, an unsaturated 9-membered heterocyclic group which has as the hetero atom at least one nitrogen atom and a bicyclic fused ring or an unsaturated 10-membered heterocyclic group which has as the hetero atom at least one nitrogen atom and a bicyclic fused ring, the heterocyclic groups optionally having alkyl, alkoxy, hydroxyl, amino, hydroxyalkyl or halogen as ring substituent and Y represents a group of the formula --(CH2)m -- in which m is an integer of 1 or 2, the group optionally having alkyl as a substituent; A group of the formula STR2 in which R1, R2, R3, R4, R5, R6, R7, R8 and R9 may be the same or different and each represents a hydrogen atom or an alkyl group; or a group of the formula STR3 in which R's may be the same or different and each represents a halogen atom or an alkyl group, n is an integer of 0 to 3 inclusive and Z is an ethylene group which may be substituted with alkyl; and X represents a halogen atom and acid addition salts thereof. The Compounds of the present invention are prepared from the corresponding 2-halogeno-ethylurea derivatives by means of conventional nitrosation procedures and useful as an antileukemic drug for various types of leukemia.